Actively Recruiting
A Comparative Study Between the Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries
Led by Ain Shams University · Updated on 2025-01-31
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of continuous adductor canal block (CACB) alone versus CACB combined with an additional posterior knee block called the infiltration between the popliteal artery and capsule of the knee (IPACK) after arthroscopic knee surgeries. The study focuses on improving pain management while preserving motor function to enable earlier physical therapy, faster recovery, and shorter hospital stays. Enhanced recovery methods after knee surgery are gaining attention, with spinal anesthesia showing benefits over general anesthesia for better pain relief and less blood loss. Participants will be randomly assigned to one of two groups: one group will receive a continuous adductor canal block alone, and the other group will receive the continuous adductor canal block plus the additional IPACK block. Both treatments aim to provide targeted nerve block for pain management while sparing motor function. The study involves a double-blind design to compare these two approaches after knee arthroscopy. During the study, participants will be monitored for pain levels 24 hours after surgery, along with total nalbuphine (opioid) consumption, ability to raise the straight leg, range of motion, and any complications. Assessments will focus on recovery progress and safety within the first day postoperatively. The trial will enroll adults aged 21 to 65 years undergoing elective arthroscopic knee surgery for ligament repair and will follow them closely after their procedures.
CONDITIONS
Brief Title
Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 21 to 65 years
- Both sexes
- American Society of Anesthesiologists (ASA) Physical Status Class I to II
- Patients with successful spinal anesthesia
- Patients scheduled for elective arthroscopic knee surgery for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) repair
You will not qualify if you...
- Declining to give written informed consent
- History of allergy to the medications used in the study
- Contraindications to regional anesthesia (including coagulopathy and local infection)
- Polytrauma patients having lower limb fractures
- Patients with pre-existing myopathy or neuropathy on the operating limb
- Patients with diabetes mellitus
- Psychiatric disorder
- Morbid obesity (body mass index over 45 kg/m2)
- Complicated surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 hours postoperatively
Participants receive either a continuous adductor canal block or a continuous adductor canal block with additional infiltration between the popliteal artery and capsule of the knee after arthroscopic knee surgery.
1 treatment period with immediate postoperative care
Trial Site Locations
Total: 1 location
1
Ain Shams University
Cairo, Egypt, 11591
Actively Recruiting
Research Team
N
Nada E Hussein, Master
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here